Mini Review

EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease†

  1. Marc Arbyn1,‡,§,*,
  2. Silvia de Sanjosé2,3,§,
  3. Mona Saraiya4,§,
  4. Mario Sideri5,§,
  5. Joel Palefsky6,
  6. Charles Lacey7,§,
  7. Maura Gillison8,§,
  8. Laia Bruni2,3,
  9. Guglielmo Ronco9,
  10. Nicolas Wentzensen10,
  11. Julia Brotherton11,§,
  12. You-Lin Qiao12,§,
  13. Lynnette Denny13,§,
  14. Jacob Bornstein14,§,
  15. Laurent Abramowitz15,
  16. Anna Giuliano16,§,
  17. Massimo Tommasino17,§,
  18. Joseph Monsonego18,§

Article first published online: 2 JUL 2012

DOI: 10.1002/ijc.27650

Issue

International Journal of Cancer

International Journal of Cancer

Volume 131, Issue 9, pages 1969–1982, 1 November 2012

Additional Information

How to Cite

Arbyn, M., de Sanjosé, S., Saraiya, M., Sideri, M., Palefsky, J., Lacey, C., Gillison, M., Bruni, L., Ronco, G., Wentzensen, N., Brotherton, J., Qiao, Y.-L., Denny, L., Bornstein, J., Abramowitz, L., Giuliano, A., Tommasino, M. and Monsonego, J. (2012), EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int. J. Cancer, 131: 1969–1982. doi: 10.1002/ijc.27650

Author Information

  1. 1

    Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium

  2. 2

    Unit of Infections and Cancer and Cancer Epidemiology Research Programme, IDIBELL, Institut Català d'Oncologia, Spain

  3. 3

    CIBER Epidemiologia y Salut Púbñica, Barcelona, Spain

  4. 4

    Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Atlanta, GA, USA

  5. 5

    Preventive Gynecology Unit, Gynecology Division, European Institute of Oncology, Milan, Italy

  6. 6

    Department of Medicine, University of California, San Francisco, San Francisco, CA, USA

  7. 7

    Hull York Medical School, University of York, Heslington, York, United Kingdom

  8. 8

    Division of Viral Oncology, Johns Hopkins, Kimmel Cancer Center, Baltimore, MD, USA

  9. 9

    Unit of Cancer Epidemiology, Centro per la prevenzione Oncologica, Turin, Italy

  10. 10

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA

  11. 11

    Victorian Cytology Service Registries, Victorian Cytology Service, East Melbourne, Vic., Australia

  12. 12

    Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China

  13. 13

    Department of Obstetrics and Gynaecology, University of Cape Town and Groote Schuur Hospital, Observatory, Cape Town, South Africa

  14. 14

    Department of Obstetrics and Gynecology, Western Galilee Hospital, Nahariya and Bar-Ilan University Faculty of Medicine, Israel

  15. 15

    Department of Gastroenterology and Proctology, Bichat University Hospital, Paris, France

  16. 16

    Department of Cancer Epidemiology, Moffitt Cancer Centre, Tampa, FL, USA

  17. 17

    International Agency for Research on Cancer, Lyon, France

  18. 18

    Institute of the Cervix, Paris, France

  1. ‡

    Tel.: +32-2-642-50-21, Fax: +32-2-642-54-10

  2. §

    Conflicts of interest: MA: Participation at Eurogin conference (Lisbon 2011) funded by organizers of the conference. SdS has an unrestricted grant from Merck and has had occasional grants for assistance to scientific meetings from GSK, MSD and Qiagen. MSi: consultancy with salary to IEO with the following companies: Qiagen, GSK, Sanofi Pasteur, MTM labs, Roche Diagnostics, Innogenetics. CL has acted as a consultant for SPMSD and received travel grants from SPMSD & GSK. MG: Merck (funding and consulting), GSK (consulting). JBr: investigator on an Australian Research Council Linkage Grant, for which CSL Biotherapies is a partner organization and was a chief investigator on a study of HPV prevalence in Australian women, which was funded by a grant from the Cooperative Research Centre for Aboriginal Health, as well as education grants in aid from GlaxoSmithKline and CSL Limited. LD has received honoraria from Merck and Glaxosmithkline for appearing on various speaker fora. And has conducted research funded by both organizations. AG: Merck (Speaker Bureau, consult, grant funding), GSK (grant funding). JM has participated to Steering Committees at Merck and to the Advisory Board of Sanofi Pasteur MSD, Gen-Probe, Qiagen and Roche Diagnostics.

*Coordinator of the Unit of Cancer Epidemiology, J. Wytsmanstreet 14, Brussels B1050, Belgium

  1. †

    Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

  2. ‡

    Tel.: +32-2-642-50-21, Fax: +32-2-642-54-10

  3. §

    Conflicts of interest: MA: Participation at Eurogin conference (Lisbon 2011) funded by organizers of the conference. SdS has an unrestricted grant from Merck and has had occasional grants for assistance to scientific meetings from GSK, MSD and Qiagen. MSi: consultancy with salary to IEO with the following companies: Qiagen, GSK, Sanofi Pasteur, MTM labs, Roche Diagnostics, Innogenetics. CL has acted as a consultant for SPMSD and received travel grants from SPMSD & GSK. MG: Merck (funding and consulting), GSK (consulting). JBr: investigator on an Australian Research Council Linkage Grant, for which CSL Biotherapies is a partner organization and was a chief investigator on a study of HPV prevalence in Australian women, which was funded by a grant from the Cooperative Research Centre for Aboriginal Health, as well as education grants in aid from GlaxoSmithKline and CSL Limited. LD has received honoraria from Merck and Glaxosmithkline for appearing on various speaker fora. And has conducted research funded by both organizations. AG: Merck (Speaker Bureau, consult, grant funding), GSK (grant funding). JM has participated to Steering Committees at Merck and to the Advisory Board of Sanofi Pasteur MSD, Gen-Probe, Qiagen and Roche Diagnostics.

Publication History

  1. Issue published online: 24 AUG 2012
  2. Article first published online: 2 JUL 2012
  3. Accepted manuscript online: 24 MAY 2012 06:12AM EST
  4. Manuscript Accepted: 24 APR 2012
  5. Manuscript Revised: 21 APR 2012
  6. Manuscript Received: 2 FEB 2012

Funded by

  • Directorate of SANCO of the European Commission, Luxembourg
  • Grand-Duchy of Luxembourg [through the ECCG project (European Cooperation on Development and Implementation of Cancer Screening and Prevention Guidelines)
  • The IARC, Lyon, France and through the EUROCHIP-3 Network (Istituto Nazionale dei Tumori, Milan, Italy)]
  • The Belgian Foundation Against Cancer (Brussels, Belgium)
  • The Intramural Research Program of the National Cancer Institute (Bethesda, USA)
  • The 7th Framework Programme of DG Research of the European Commission (PREHDICT Project, coordinated by the Vrije Universiteit Amsterdam, the Netherlands). Grant Number: 242061
  • The HPV-AHEAD Project (coordinated by IARC). Grant Number: FP7-HEALTH-2011-282562

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (350K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article (HTML) Get PDF (350K)